Dry Eye Disease Market
- As per DelveInsight analysis, the Dry Eye Disease market is anticipated to witness growth at a considerable CAGR.
- The total Dry Eye Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the Dry Eye Disease market.
- The dynamics of the DED market is anticipated to experience a positive shift in the coming years owing to the expectedlaunch of a barrage of emerging therapies, i.e. OK-101 (Okyo Pharma), PL9643 (Palatin Technologies), and many othersduring the forecast period, 2022–2032.
- Key companies working in the Dry Eye Disease market are Palatin Technologies, Novaliq, Mc2 therapeutics, and others.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Eye Disease market report provides current treatment practices, emerging drugs, Dry Eye Disease market share of the individual therapies, current and forecasted Dry Eye Disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Dry Eye Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Dry Eye Disease market.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2019-2032
Dry Eye Disease Disease Understanding and Treatment Algorithm
Dry eye disease, also referred to as dry eye syndrome or keratoconjunctivitis sicca, is a prevalent condition characterized by insufficient tear production or rapid evaporation of tears. This insufficiency results in the eyes drying out, leading to redness, swelling, and irritation. Contributing factors to DED encompass reduced tear production, excessive tear evaporation, and abnormalities in mucus or lipid production in the tear layer. This chronic lack of proper lubrication and moisture on the eye surface can range from persistent eye discomfort to severe inflammation and potential scarring of the eye's front surface. Dry eye disease can impact one or both eyes and has the potential to cause inflammation.
Dry Eye Disease Symptoms
The primary indication of dry eye is a sensation of dryness and grittiness within the eyes. Additional symptoms encompass a burning or itching sensation, feeling like a foreign object is present, excessive tearing, eye pain, redness, and occasionally light sensitivity. Some individuals may experience a stringy discharge and notice fluctuations in their vision clarity. Furthermore, these symptoms tend to intensify in dry climates, low-humidity conditions, and higher temperatures. Prolonged periods of dry eyes can result in minor abrasions on the eye surface. In more severe instances, there can be pathological alterations in the epithelium, including squamous metaplasia and a reduction in goblet cells.
Dry Eye Disease Treatment
It covers the details of conventional and current medical therapies available in the Dry Eye Disease market for the treatment of the condition. It also provides Dry Eye Disease treatment algorithms and guidelines in the United States, Europe, and Japan.
The Dry Eye Disease epidemiology section provides insights about the historical and current Dry Eye Disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Dry Eye Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
- According to DelveInsight’s analysis, females are more affected by DED than males.
- According to Siffel et. al (2020), the prevalence and incidence of DED increased with age and were higher inwomen in Germany.
- According to Stapleton et al. (2017), study the global prevalence estimates of DED was reported to be 5–50%with estimates in Europe (specifically, France and UK) ranging from 10% to 22%.
Country Wise- Dry Eye Disease Epidemiology
The epidemiology segment also provides the Dry Eye Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Dry Eye Disease Drug Chapters
The drug chapter segment of the Dry Eye Disease report encloses the detailed analysis of Dry Eye Disease marketed drugs and late-stage (Phase-III and Phase-II) Dry Eye Disease pipeline drugs. It also helps to understand the Dry Eye Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Dry Eye Disease Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Dry Eye Disease treatment.
Dry Eye Disease Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Dry Eye Disease treatment.
Dry Eye Disease Market Outlook
The Dry Eye Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dry Eye Disease market trends by analyzing the impact of current Dry Eye Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
The treatments of Dry Eye Disease are varied. The goals of treatment are to relieve the symptoms of dry eye, improve the patient’scomfort, return the ocular surface and tear film to the normal state, and, whenever possible, prevent corneal damage.Treatment may range from education, environmental or dietary modifications, artificial tear substitutes, punctual plugs, andtopical and/or systemic anti-inflammatory medications to surgery.
Historically, Dry Eye Disease was considered to be largely due to tear insufficiency and was treated by prescribing tear replacementproducts or by conserving the tears via punctual plugs. More recent treatments have included the use of methods to stimulatetears.
According to DelveInsight, the Dry Eye Disease market in 7MM is expected to witness a major change in the study period 2019-2032.
- Numerous companies are actively engaged in continuous research efforts focused on enhancing our understanding of inflammatory pathways and targeting various inflammatory mediators in patients suffering from dry eye. Recent progress in comprehending the physiology and pathology of the tear film has led to the creation of diverse tear substitutes designed to address specific deficiencies in tear components. Additionally, the anticipated validation of safety and effectiveness in ongoing trials, along with the introduction of new therapies, is projected to propel market growth between 2019 and 2032.
- Major pharmaceutical companies are deeply invested in pioneering novel treatment approaches to offer enhanced relief for symptoms and ultimately enhance the quality of life for individuals affected by DED. Key industry players such as OkyoPharma, Palatin Technologies, Stuart Therapeutics, among others, are actively involved in developing therapies specifically tailored for Dry Eye Disease (DED). Their efforts are expected to significantly alter the landscape of the Dry Eye Disease market in the coming years.
The United States Market Outlook
This section provides the total Dry Eye Disease market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Dry Eye Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Dry Eye Disease market size and market size by therapies in Japan is also mentioned.
Dry Eye Disease Drugs Uptake
"Several approved therapies drive the current therapeutic landscape of Dry Eye Disease in the 7MM. The market for Dry Eye Disease is estimated to increase by 2032. The major reason for the market upsurge is the launch of the most anticipated therapies, which are considered as a threat to the current market."
This section focuses on the rate of uptake of the potential Dry Eye Disease drugs recently launched in the Dry Eye Disease market or expected to get launched in the market during the study period 2019-2032. The analysis covers Dry Eye Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Dry Eye Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Dry Eye Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Dry Eye Disease Pipeline Development Activities
The Dry Eye Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Dry Eye Disease key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Dry Eye Disease report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Dry Eye Disease emerging therapies.
Reimbursement Scenario in Dry Eye Disease
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current Dry Eye Disease market trends, we take KOLs and SMEs ' opinion working in the Dry Eye Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dry Eye Disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Dry Eye Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
2019 to 2032
2023 to 2032
USD XX Million in 2021
Key Dry Eye Disease Companies
Palatin Technologies, Novaliq, Mc2 therapeutics, and many others.
Scope of the Report
- The report covers the descriptive overview of Dry Eye Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Dry Eye Disease epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Dry Eye Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Dry Eye Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dry Eye Disease market
- In the coming years, the Dry Eye Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Dry Eye Disease. The launch of emerging therapies will significantly impact the Dry Eye Disease market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dry Eye Disease
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Dry Eye Disease Report Insights
- Dry Eye Disease Patient Population
- Therapeutic Approaches
- Dry Eye Disease Pipeline Analysis
- Dry Eye Disease Market Size and Trends
- Dry Eye Disease Market Opportunities
- Impact of upcoming Dry Eye Disease Therapies
Dry Eye Disease Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Dry Eye Disease Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Dry Eye Disease Report Assessment
- Current Treatment Practices
- Unmet Needs
- Dry Eye Disease Pipeline Product Profiles
- Dry Eye Disease Market Attractiveness
- Market Drivers and Barriers
- What was the Dry Eye Disease drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Dry Eye Disease total market size as well as market size by therapies across the 7MM during the forecast period (2023-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Dry Eye Disease market size during the forecast period (2023-2032)?
- At what CAGR, the Dry Eye Disease market is expected to grow by 7MM during the forecast period (2023-2032)?
- What would be the Dry Eye Disease market outlook across the 7MM during the forecast period (2023-2032)?
- What would be the Dry Eye Disease market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
- What are the disease risk, burden, and regional/ethnic differences of the Dry Eye Disease?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Dry Eye Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Dry Eye Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dry Eye Disease?
- Out of all 7MM countries, which country would have the highest prevalent population of Dry Eye Disease during the forecast period (2023-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2023-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Dry Eye Disease treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Dry Eye Disease in the USA, Europe, and Japan?
- What are the Dry Eye Disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Dry Eye Disease?
- How many therapies are in-development by each company for Dry Eye Disease treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Dry Eye Disease treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dry Eye Disease and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Dry Eye Disease?
- What are the global historical and forecasted market of Dry Eye Disease?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Dry Eye Disease market
- To understand the future market competition in the Dry Eye Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Dry Eye Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Dry Eye Disease market
- To understand the future market competition in the Dry Eye Disease market